Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05237947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Study acronym: PRISMA
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 21, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 30 days later Aug 31, 2026 → Sep 30, 2026
See other at-risk trials from National Cancer Institute (NCI)

Record History

  1. Primary completion pushed from Aug 31, 2026 to Sep 30, 2026 Interventions: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Questionnaire Administration (Other), Recombinant Human… to Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Questionnaire Administration (Other), Recombinant Human… · Eligibility criteria expanded, about 27 words · Secondary endpoints: details revised at 3 of 4 entries · 2 more Show 5 more changesShow less
    • Interventions: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Questionnaire Administration (Other), Recombinant Human… to Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Questionnaire Administration (Other), Recombinant Human…
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  2. Primary completion pushed from May 31, 2026 to Aug 31, 2026 Completion pushed from May 31, 2026 to Dec 31, 2026v38 Show 1 more changeShow less
    • Completion pushed from May 31, 2026 to Dec 31, 2026
  3. Primary endpoint(s) modified Eligibility criteria revised · Secondary endpoints revised (4) · Study description expanded, about 57 wordsv37 Show 3 more changesShow less
    • Eligibility criteria revised
    • Secondary endpoints revised (4)
    • Study description expanded, about 57 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv36
  5. Primary endpoint(s) modified Secondary endpoints: 7 to 4 · Study description expanded, about 114 wordsv35 Show 2 more changesShow less
    • Secondary endpoints: 7 to 4
    • Study description expanded, about 114 words

    See this version in full on ClinicalTrials.gov ↗

Show 33 earlier versionsHide 33 earlier versions
  1. 17 versions Re-verified since Mar 18, 2026, no change to tracked fieldsv18-v34
  2. Primary endpoint revised Secondary endpoints: details revised at 5 of 7 entriesv17 Show 1 more changeShow less
    • Secondary endpoints: details revised at 5 of 7 entries

    See this version in full on ClinicalTrials.gov ↗

  3. 6 versions Re-verified since Mar 2, 2024, no change to tracked fieldsv11-v16
  4. Trial status: Enrolling by Invitation to Active, Not Recruitingv10
  5. Study site revisedv9 See this version in full on ClinicalTrials.gov ↗
  6. 3 versions Re-verified since Jun 7, 2022, no change to tracked fieldsv6-v8
  7. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date changed from estimate of Mar 7, 2022 to Mar 1, 2022 · Site contact updatedv5 Show 2 more changesShow less
    • Start date changed from estimate of Mar 7, 2022 to Mar 1, 2022
    • Site contact updated
  8. Eligibility criteria revisedv4 See this version in full on ClinicalTrials.gov ↗
  9. Secondary endpoints: details revised at 7 of 7 entriesv3
  10. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.
Trial Details
NCT Number NCT05237947
Lead Sponsor National Cancer Institute (NCI)
Conditions Human Papillomavirus-Related Cervical Carcinoma
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov